TY  - JOUR
AU  - Romero-Sanchiz, Pablo
AU  - Nogueira-Arjona, Raquel
AU  - Pastor, Antoni
AU  - Araos, Pedro
AU  - Serrano, Antonia
AU  - Boronat, Anna
AU  - Garcia-Marchena, Nuria
AU  - Mayoral, Fermin
AU  - Bordallo, Antonio
AU  - Alen, Francisco
AU  - Suárez, Juan
AU  - de la Torre, Rafael
AU  - Pavón, Francisco J
AU  - Rodríguez de Fonseca, Fernando
PY  - 2019
DO  - 10.1016/j.neuropharm.2019.02.026
UR  - http://hdl.handle.net/10668/13645
T2  - Neuropharmacology
AB  - Oleoylethanolamide (OEA) is a non-cannabinoid acylethanolamide with multiple physiological roles that has been proposed to have antidepressant-like activity in preclinical models. OEA shares biosynthetic pathways with anandamide (AEA) a transmitter...
LA  - en
KW  - Acylethanolamides
KW  - Anandamide
KW  - Antidepressants
KW  - Depression
KW  - Endocannabinoids
KW  - Oleoylethanolamide
KW  - Primary care
KW  - Adult
KW  - Antidepressive Agents
KW  - Arachidonic Acids
KW  - Depression
KW  - Endocannabinoids
KW  - Ethanolamines
KW  - Female
KW  - Healthy Volunteers
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Monoglycerides
KW  - Oleic Acids
KW  - Polyunsaturated Alkamides
KW  - Primary Health Care
KW  - Selective Serotonin Reuptake Inhibitors
TI  - Plasma concentrations of oleoylethanolamide in a primary care sample of depressed patients are increased in those treated with selective serotonin reuptake inhibitor-type antidepressants.
TY  - research article
VL  - 149
ER  -